GCP
RCUS icon

Gill Capital Partners’s Arcus Biosciences RCUS Stock Holding History

Gill Capital Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08K Buy
+50
New +$1.08K ﹤0.01% 594

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Gill Capital Partners's RCUS Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 50 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #594 among its holdings.

210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Gill Capital Partners held 50 shares of Arcus Biosciences worth $1.08K as of Q1 2026.
  • Arcus Biosciences was a new Gill Capital Partners position in Q1 2026.
  • Arcus Biosciences made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #594 holding.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.